Clinical trial results for
early-stage non-small
cell lung cancer
(NSCLC) before surgery
Given before surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery
Clinical trial results for
early-stage non-small
cell lung cancer
(NSCLC) before surgery
Given before surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery
Actor portrayals.
OPDIVO + chemotherapy is not approved for
people younger than 18 years of age.
Your doctor has determined having surgery will be an important step for you to take in treating your early-stage non-small cell lung cancer, but to make sure the tumor is small enough to be removed and that no hidden or hard to see cells are left, your doctor may recommend a pre-surgery treatment.
In a clinical trial of 358 people with early-stage NSCLC who were able to have surgery, 179 people were given OPDIVO + chemotherapy before surgery, and 179 people were given platinum-based chemotherapy before surgery.
Half the people remained free of cancer spreading or returning
Half the people remained free of cancer spreading or returning
OPDIVO + chemotherapy given before surgery was proven to reduce the risk of their cancer spreading or returning by 37% compared to chemotherapy alone.
OPDIVO + chemotherapy will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For adults with early-stage non-small cell lung cancer (NSCLC) before surgery
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early-stage lung cancer (called non-small cell lung cancer).
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.